CN101951956B - 用于水溶性差的药用活性物质给药的药物递送系统 - Google Patents

用于水溶性差的药用活性物质给药的药物递送系统 Download PDF

Info

Publication number
CN101951956B
CN101951956B CN2008801270180A CN200880127018A CN101951956B CN 101951956 B CN101951956 B CN 101951956B CN 2008801270180 A CN2008801270180 A CN 2008801270180A CN 200880127018 A CN200880127018 A CN 200880127018A CN 101951956 B CN101951956 B CN 101951956B
Authority
CN
China
Prior art keywords
retinoyl
methyl ester
sodium salt
drug delivery
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801270180A
Other languages
English (en)
Chinese (zh)
Other versions
CN101951956A (zh
Inventor
朱莉安·阿列克索夫
伊戈尔·洛科特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vistor Co
Original Assignee
Ardenia Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40795732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101951956(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardenia Investments Ltd filed Critical Ardenia Investments Ltd
Publication of CN101951956A publication Critical patent/CN101951956A/zh
Application granted granted Critical
Publication of CN101951956B publication Critical patent/CN101951956B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008801270180A 2007-12-19 2008-12-18 用于水溶性差的药用活性物质给药的药物递送系统 Active CN101951956B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SEPCT/SE2007/001127 2007-12-19
PCT/SE2007/001127 WO2009078754A1 (en) 2007-12-19 2007-12-19 Drug delivery system for administration of poorly water soluble pharmaceutically active substances
PCT/SE2008/051515 WO2009078802A1 (en) 2007-12-19 2008-12-18 Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Publications (2)

Publication Number Publication Date
CN101951956A CN101951956A (zh) 2011-01-19
CN101951956B true CN101951956B (zh) 2012-10-17

Family

ID=40795732

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801270180A Active CN101951956B (zh) 2007-12-19 2008-12-18 用于水溶性差的药用活性物质给药的药物递送系统

Country Status (27)

Country Link
US (4) US8999382B2 (https=)
EP (1) EP2231189B1 (https=)
JP (1) JP5466172B2 (https=)
KR (1) KR101572703B1 (https=)
CN (1) CN101951956B (https=)
AU (1) AU2008339099B2 (https=)
BR (1) BRPI0821740B1 (https=)
CA (1) CA2709266C (https=)
CY (2) CY1119805T1 (https=)
DK (1) DK2231189T3 (https=)
EA (1) EA015247B1 (https=)
ES (1) ES2650242T3 (https=)
FR (1) FR19C1030I1 (https=)
HR (1) HRP20171796T1 (https=)
HU (1) HUE034684T2 (https=)
LT (2) LT2231189T (https=)
LU (1) LUC00117I2 (https=)
MX (1) MX2010006914A (https=)
MY (2) MY157187A (https=)
NL (1) NL300987I9 (https=)
NO (2) NO2231189T3 (https=)
NZ (1) NZ586859A (https=)
PL (1) PL2231189T3 (https=)
PT (1) PT2231189T (https=)
SI (1) SI2231189T1 (https=)
WO (2) WO2009078754A1 (https=)
ZA (1) ZA201004685B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078755A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
KR20120022984A (ko) * 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Ｔｈ１ 편향 반응을 제공하는 면역나노치료법
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
CN103908432B (zh) * 2013-01-02 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种伊沙匹隆白蛋白的冻干组合物及其制备方法
CN112321465B (zh) 2019-07-18 2023-06-06 上海现代药物制剂工程研究中心有限公司 一种含苯基化合物、其中间体、制备方法及应用
CN112239418B (zh) * 2019-07-18 2023-07-07 上海现代药物制剂工程研究中心有限公司 视黄醇类化合物及其钠盐的制备方法
WO2021259472A1 (en) * 2020-06-24 2021-12-30 Oasmia Pharmaceutical Ab Micellar docetaxel for use in the treatment of cancer
CN115429886B (zh) * 2021-06-02 2025-10-31 复旦大学 一种药物纳米结晶制剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668583A (zh) * 2002-07-23 2005-09-14 阿登尼亚投资有限公司 视黄醇衍生物、它们在治疗癌症和增强其它细胞毒性剂功效中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
SE0101702D0 (sv) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
SE0202311D0 (sv) * 2002-07-23 2002-07-23 Ardenia Investments Ltd Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment
US7259984B2 (en) * 2002-11-26 2007-08-21 Cornell Research Foundation, Inc. Multibit metal nanocrystal memories and fabrication
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
WO2005089106A2 (en) 2004-02-27 2005-09-29 Molecular Therapeutics, Inc. Degradable nanoparticles
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
US8945629B2 (en) * 2004-09-10 2015-02-03 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
AU2006284657B2 (en) * 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078755A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668583A (zh) * 2002-07-23 2005-09-14 阿登尼亚投资有限公司 视黄醇衍生物、它们在治疗癌症和增强其它细胞毒性剂功效中的应用

Also Published As

Publication number Publication date
CN101951956A (zh) 2011-01-19
NL300987I9 (nl) 2019-05-16
AU2008339099B2 (en) 2015-08-13
HRP20171796T1 (hr) 2018-01-26
BRPI0821740B1 (pt) 2021-05-18
CY1119805T1 (el) 2018-06-27
NO2231189T3 (https=) 2018-02-03
ZA201004685B (en) 2011-03-30
EA200802350A3 (ru) 2009-10-30
NL300987I2 (https=) 2019-05-09
LUC00117I2 (https=) 2024-05-22
EA200802350A2 (ru) 2009-06-30
CY2019021I2 (el) 2019-11-27
AU2008339099A1 (en) 2009-06-25
LTPA2019508I1 (lt) 2019-05-10
KR20100094575A (ko) 2010-08-26
EP2231189A4 (en) 2013-10-09
PL2231189T3 (pl) 2018-03-30
MY157187A (en) 2016-05-13
MX2010006914A (es) 2010-11-10
ES2650242T3 (es) 2018-01-17
EA015247B1 (ru) 2011-06-30
JP5466172B2 (ja) 2014-04-09
US20110014281A1 (en) 2011-01-20
DK2231189T3 (en) 2017-12-11
NZ586859A (en) 2012-06-29
BRPI0821740A2 (pt) 2020-02-27
USRE49741E1 (en) 2023-12-05
USRE49742E1 (en) 2023-12-05
US9993438B2 (en) 2018-06-12
JP2011507838A (ja) 2011-03-10
EP2231189B1 (en) 2017-09-06
MY157186A (en) 2016-05-13
CA2709266C (en) 2017-09-26
CY2019021I1 (el) 2019-11-27
NO2019023I1 (no) 2019-05-08
US20150164819A1 (en) 2015-06-18
US8999382B2 (en) 2015-04-07
FR19C1030I1 (fr) 2019-06-21
EP2231189A1 (en) 2010-09-29
LT2231189T (lt) 2017-12-27
HUE034684T2 (en) 2018-02-28
WO2009078754A1 (en) 2009-06-25
SI2231189T1 (en) 2018-03-30
WO2009078802A1 (en) 2009-06-25
CA2709266A1 (en) 2009-06-25
PT2231189T (pt) 2017-12-12
KR101572703B1 (ko) 2015-11-27

Similar Documents

Publication Publication Date Title
CN101951956B (zh) 用于水溶性差的药用活性物质给药的药物递送系统
ES2435944T3 (es) Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso
JP2017114913A (ja) ナノ粒子処方物およびその使用
CN102056596A (zh) 纳米颗粒制剂及其用途
JP2011517683A (ja) 疎水性タキサン誘導体の組成物およびその使用
CN101291658A (zh) 用于制备稳定性增加的水难溶性药物的组合物和方法
CN104587479A (zh) 组合物和传递药剂的方法
KR20140027554A (ko) 약리학적 물질의 조성물 및 그 전달방법
CN101945670B (zh) 用于水溶性阳离子两亲性药用活性物质给药的药物递送系统
CN101945671B (zh) 用于水溶性阳离子两亲性的药用活性物质给药的药物递送系统
CN107519496B (zh) 一类l-肉毒碱两亲性衍生物及其修饰的纳米粒及其用途
CN112741828B (zh) 药物联用物及其制备方法和用途
CN112121028B (zh) 一种辛伐他汀固体纳米粒制剂及其制备方法
RU2522977C2 (ru) Композиции и способы доставки фармакологических агентов
CN1925874B (zh) 组合物和传递药剂的方法
HK1191253A (en) Compositions and methods of delivery of pharmacological agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210428

Address after: uppsala

Patentee after: Oswald MIA pharmaceutical Co.

Address before: London, England

Patentee before: ARDENIA INVESTMENTS, Ltd.

TR01 Transfer of patent right
CP01 Change in the name or title of a patent holder

Address after: uppsala

Patentee after: Vistor Co.

Address before: uppsala

Patentee before: Oswald MIA pharmaceutical Co.

CP01 Change in the name or title of a patent holder
IP01 Partial invalidation of patent right

Commission number: 4W114046

Conclusion of examination: On the basis of claims 1-27 submitted by the patentee on May 9, 2022, continue to maintain the validity of invention patent right No. 200880127018.0

Decision date of declaring invalidation: 20221205

Decision number of declaring invalidation: 59398

Denomination of invention: Drug delivery system for the administration of poorly water-soluble medicinal active substances

Granted publication date: 20121017

Patentee: Weiweisiduo Company

IP01 Partial invalidation of patent right